Leflukind 20 – Leflunomide IP 20 mg Tablets

Product Overview

Leflukind 20 is an oral pharmaceutical formulation containing Leflunomide IP 20 mg, presented in tablet dosage form. The product is supplied in a 10×10 tablet pack, containing a total of 100 tablets.

Leflunomide is a disease-modifying antirheumatic drug (DMARD) used in the treatment of active rheumatoid arthritis in adults. Unlike medicines that are primarily intended to provide short-term symptomatic relief, leflunomide acts on the underlying immune-mediated disease process and helps reduce disease activity over time.

The formulation is therefore relevant to pharmaceutical portfolios focused on rheumatology, rheumatoid arthritis, orthopedic care and disease-modifying anti-inflammatory therapy.

What Is Leflukind 20 Used For?

Leflukind 20 contains leflunomide and is used for the treatment of active rheumatoid arthritis in adults. Rheumatoid arthritis is a chronic autoimmune disorder in which the immune system attacks joint tissues, resulting in inflammation, pain, swelling, stiffness and progressive loss of joint function.

Leflunomide helps control disease activity and may slow the progression of rheumatoid arthritis. It belongs to the DMARD class and is intended for disease management rather than simply providing temporary relief from joint pain.

How Does Leflunomide Work?

Leflunomide acts by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis. This reduces the proliferation of activated lymphocytes involved in the autoimmune inflammatory response associated with rheumatoid arthritis.

By modulating this immune response, leflunomide helps reduce inflammatory disease activity and can contribute to improved joint function and control of rheumatoid arthritis symptoms.

Composition

Each tablet contains:

Leflunomide IP – 20 mg

Product Specifications

Key Product Highlights

• Contains Leflunomide IP 20 mg

• Oral tablet formulation

• Disease-modifying antirheumatic drug

• Used for active rheumatoid arthritis in adults

• Supports long-term management of rheumatoid disease activity

• Relevant to rheumatology-focused pharmaceutical portfolios

• 20 mg strength

• Convenient 10×10 tablet presentation

• Total pack quantity of 100 tablets

Rheumatoid Arthritis and Disease Management

Rheumatoid arthritis is a systemic autoimmune condition that primarily affects the joints. Persistent inflammation can result in joint damage, stiffness, reduced mobility and impaired physical function.

Disease-modifying antirheumatic drugs are used to control the underlying inflammatory and autoimmune process rather than relying only on medicines that temporarily reduce pain. Leflunomide is one such DMARD and is used to manage active rheumatoid arthritis in adults.

This makes Leflukind 20 a relevant formulation for pharmaceutical portfolios serving the rheumatology and chronic joint-disease management segment.

B2B Pharma Portfolio Relevance

Leflukind 20 can be considered for pharmaceutical portfolios focused on rheumatology, rheumatoid arthritis and disease-modifying therapies.

The product provides a dedicated Leflunomide 20 mg tablet formulation for pharmaceutical businesses developing a focused range of prescription medicines for chronic inflammatory and autoimmune joint disorders.

Its established DMARD classification, 20 mg strength and tablet presentation make it relevant to specialized pharmaceutical product portfolios serving appropriate healthcare channels.

Why Consider Leflukind 20?

Leflukind 20 offers a focused formulation for the rheumatoid arthritis segment with:

• Leflunomide 20 mg composition

• DMARD-based therapeutic positioning

• Oral tablet dosage form

• Rheumatology-focused application

• Relevance to chronic rheumatoid arthritis management

• 10×10 tablet commercial presentation

• 100 tablets per pack

• Suitability for specialized pharmaceutical portfolios

Packing Information

Dosage Form: Tablet

Strength: 20 mg

Packing: 10 × 10 Tablets

Total Quantity: 100 Tablets

The latest approved product specification should be referred to for final regulatory, commercial and ordering information.

Important Medical Information

Leflunomide is a prescription DMARD that requires appropriate medical supervision. It can cause serious adverse effects, including liver injury and bone-marrow suppression, and requires appropriate clinical and laboratory monitoring. It is contraindicated during pregnancy because of the risk of fetal harm.

Product use, monitoring and treatment duration should therefore follow the approved prescribing information and the treating physician's instructions.

Ideal Pharmaceutical Portfolio Segment

Leflukind 20 is relevant for pharmaceutical businesses developing or maintaining portfolios in:

• Rheumatology

• Rheumatoid Arthritis

• Orthopedic Care

• Disease-Modifying Antirheumatic Therapy

• Chronic Inflammatory Joint Disorders

• Immunomodulatory Therapy

Business Enquiry

For product availability, commercial information and pharmaceutical business enquiries related to Leflukind 20, contact Farlex Pharmaceuticals Pvt. Ltd.